Mizolastine

DB12523ApprovedSmall molecule

Mizolastine is a second-generation non-sedating antihistamine used to treat symptoms of allergic rhinoconjunctivitis and urticaria. Mizolastine is under investigation in clinical trial NCT01928316 (A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers).

Chemical structure of Mizolastine
Mechanism
Curator reviewed
Formula / weight
C24H25FN6O · 432.503 g/mol (avg)
Code names
CCRIS 8410 · SL 85.0324

Resolves to

Compound
UNII244O1F90NACAS108612-45-9ChEMBLCHEMBL94454ChEBI31857PubChem65906
Clinical / RWD
RxNorm61455ATCR06AX25PharmGKBPA166129535
Structure
InChIKeyPVLJETXTTWAYEW-UHFFFAOYSA-NSMILESCN(C1CCN(CC1)C1=NC2=C(C=CC=C2)N1CC1=CC=C(F)C=C1)C1=NC=CC(=O)N1
Targets
P35367HRH1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
422Drug interactionsStructured to mechanism, not free text
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
10ContraindicationsEach with its own population and attribute set
Sign in
103Marketed productsAcross 3 countries and 3 labellers
Sign in
1ATC codeIncluding every combination product, plus 12 drug categories
Sign in
12+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Mizolastine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In